Supports investigator-initiated clinical trials for neurological disorders, from early exploratory studies to Phase 3 confirmatory and comparative effectiveness trials.
Funder: National Institutes of Health
Due Dates: February 10, 2027 (New) | March 10, 2027 (Renewal/Resubmission/Revision) | June 10, 2027 (New) | July 9, 2027 (Renewal/Resubmission/Revision) | October 8, 2027 (New) | November 8, 2027 (Renewal/Resubmission/Revision) | February 10, 2028 (New) | March 10, 2028 (Renewal/Resubmission/Revision) | June 9, 2028 (New) | July 10, 2028 (Renewal/Resubmission/Revision) | October 10, 2028 (New) | November 9, 2028 (Renewal/Resubmission/Revision) | February 9, 2029 (New) | March 9, 2029 (Renewal/Resubmission/Revision; final closing)
Funding Amounts: No budget cap; budgets must reflect project needs; up to 7 years total; no cost sharing required
Summary: Supports investigator-initiated exploratory, confirmatory, and comparative effectiveness clinical trials of interventions for neurological disorders.
Key Information: Clinical trials are required; applications involving foreign subawards or subcontracts are not eligible for funding.
The National Institute of Neurological Disorders and Stroke (NINDS) supports investigator-initiated clinical trials developing interventions to prevent neurological disorders or improve their outcomes. Supported interventions include small molecules, biologics, devices, surgery, behavioral treatments, diet-based therapies, and rehabilitation. Studies addressing neurological diseases and care across the lifespan are highly encouraged.
This opportunity supports early- and middle-phase exploratory trials, later-phase confirmatory or pivotal trials, comparative effectiveness trials, and seamless Phase 2/3 designs. Pragmatic trials with minimal changes to clinical practice and low per-participant costs are encouraged, as are rare-disease trials. The milestone-driven UG3/UH3 cooperative agreement begins with planning, start-up, and feasibility work, followed by full trial implementation only after satisfactory progress and administrative review.